vs
百富门（BF.B）与MEDIFAST INC（MED）财务数据对比。点击上方公司名可切换其他公司
百富门的季度营收约是MEDIFAST INC的13.8倍（$1.0B vs $75.1M）。百富门同比增速更快（-5.4% vs -36.9%）。百富门自由现金流更多（$107.0M vs $-6.6M）。过去两年百富门的营收复合增速更高（-1.6% vs -34.4%）
百富门（Brown-Forman）是美国家族控股上市企业，属全球规模最大的葡萄酒及烈酒经营集团之一，总部位于肯塔基州路易斯维尔。旗下拥有杰克丹尼、伍德福德珍藏、格兰多纳等多个国际知名酒类品牌，曾持有的南方安逸等品牌已于2016年出售。
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
BF.B vs MED — 直观对比
营收规模更大
BF.B
是对方的13.8倍
$75.1M
营收增速更快
BF.B
高出31.5%
-36.9%
自由现金流更多
BF.B
多$113.6M
$-6.6M
两年增速更快
BF.B
近两年复合增速
-34.4%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $75.1M |
| 净利润 | $224.0M | — |
| 毛利率 | 59.4% | 69.4% |
| 营业利润率 | 29.4% | -10.4% |
| 净利率 | 21.6% | — |
| 营收同比 | -5.4% | -36.9% |
| 净利润同比 | -13.2% | — |
| 每股收益（稀释后） | $0.47 | $-1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BF.BMED
| Q4 25 | $1.0B | $75.1M | ||
| Q3 25 | $924.0M | $89.4M | ||
| Q2 25 | $894.0M | $105.6M | ||
| Q1 25 | $1.0B | $115.7M | ||
| Q4 24 | $1.1B | $119.0M | ||
| Q3 24 | $951.0M | $140.2M | ||
| Q2 24 | $964.0M | $168.6M | ||
| Q1 24 | $1.1B | $174.7M |
净利润BF.BMED
| Q4 25 | $224.0M | — | ||
| Q3 25 | $170.0M | $-2.3M | ||
| Q2 25 | $146.0M | $2.5M | ||
| Q1 25 | $270.0M | $-772.0K | ||
| Q4 24 | $258.0M | — | ||
| Q3 24 | $195.0M | $1.1M | ||
| Q2 24 | $266.0M | $-8.2M | ||
| Q1 24 | $285.0M | $8.3M |
毛利率BF.BMED
| Q4 25 | 59.4% | 69.4% | ||
| Q3 25 | 59.7% | 69.5% | ||
| Q2 25 | 57.4% | 72.6% | ||
| Q1 25 | 59.8% | 72.8% | ||
| Q4 24 | 59.0% | 74.1% | ||
| Q3 24 | 59.4% | 75.4% | ||
| Q2 24 | 59.0% | 73.2% | ||
| Q1 24 | 59.4% | 72.8% |
营业利润率BF.BMED
| Q4 25 | 29.4% | -10.4% | ||
| Q3 25 | 28.1% | -4.6% | ||
| Q2 25 | 22.9% | -1.0% | ||
| Q1 25 | 27.1% | -1.1% | ||
| Q4 24 | 31.1% | 0.6% | ||
| Q3 24 | 29.5% | 1.5% | ||
| Q2 24 | 38.9% | -4.7% | ||
| Q1 24 | 34.9% | 4.5% |
净利率BF.BMED
| Q4 25 | 21.6% | — | ||
| Q3 25 | 18.4% | -2.5% | ||
| Q2 25 | 16.3% | 2.3% | ||
| Q1 25 | 26.1% | -0.7% | ||
| Q4 24 | 23.6% | — | ||
| Q3 24 | 20.5% | 0.8% | ||
| Q2 24 | 27.6% | -4.8% | ||
| Q1 24 | 26.7% | 4.8% |
每股收益（稀释后）BF.BMED
| Q4 25 | $0.47 | $-1.64 | ||
| Q3 25 | $0.36 | $-0.21 | ||
| Q2 25 | $0.31 | $0.22 | ||
| Q1 25 | $0.57 | $-0.07 | ||
| Q4 24 | $0.55 | $0.08 | ||
| Q3 24 | $0.41 | $0.10 | ||
| Q2 24 | $0.56 | $-0.75 | ||
| Q1 24 | $0.60 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $319.0M | $167.3M |
| 总债务越低越好 | $2.4B | — |
| 股东权益账面价值 | $4.1B | $198.9M |
| 总资产 | $8.2B | $248.0M |
| 负债/权益比越低杠杆越低 | 0.59× | — |
8季度趋势，按日历期对齐
现金及短期投资BF.BMED
| Q4 25 | $319.0M | $167.3M | ||
| Q3 25 | $471.0M | $173.5M | ||
| Q2 25 | $444.0M | $162.7M | ||
| Q1 25 | $599.0M | $164.6M | ||
| Q4 24 | $416.0M | $162.3M | ||
| Q3 24 | $416.0M | $170.0M | ||
| Q2 24 | $446.0M | $163.5M | ||
| Q1 24 | $589.0M | $156.4M |
总债务BF.BMED
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
股东权益BF.BMED
| Q4 25 | $4.1B | $198.9M | ||
| Q3 25 | $4.0B | $214.7M | ||
| Q2 25 | $4.0B | $216.0M | ||
| Q1 25 | $3.8B | $211.0M | ||
| Q4 24 | $3.7B | $210.1M | ||
| Q3 24 | $3.5B | $207.3M | ||
| Q2 24 | $3.5B | $205.3M | ||
| Q1 24 | $3.2B | $211.0M |
总资产BF.BMED
| Q4 25 | $8.2B | $248.0M | ||
| Q3 25 | $8.2B | $268.2M | ||
| Q2 25 | $8.1B | $269.3M | ||
| Q1 25 | $8.1B | $280.0M | ||
| Q4 24 | $8.3B | $284.2M | ||
| Q3 24 | $8.2B | $291.2M | ||
| Q2 24 | $8.2B | $293.5M | ||
| Q1 24 | $8.2B | $302.8M |
负债/权益比BF.BMED
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $132.0M | $-5.3M |
| 自由现金流经营现金流 - 资本支出 | $107.0M | $-6.6M |
| 自由现金流率自由现金流/营收 | 10.3% | -8.8% |
| 资本支出强度资本支出/营收 | 2.4% | 1.8% |
| 现金转化率经营现金流/净利润 | 0.59× | — |
| 过去12个月自由现金流最近4个季度 | $610.0M | $1.2M |
8季度趋势，按日历期对齐
经营现金流BF.BMED
| Q4 25 | $132.0M | $-5.3M | ||
| Q3 25 | $160.0M | $12.1M | ||
| Q2 25 | $152.0M | $-3.4M | ||
| Q1 25 | $317.0M | $3.4M | ||
| Q4 24 | $112.0M | $-4.9M | ||
| Q3 24 | $17.0M | $9.1M | ||
| Q2 24 | $285.0M | $13.1M | ||
| Q1 24 | $265.0M | $7.3M |
自由现金流BF.BMED
| Q4 25 | $107.0M | $-6.6M | ||
| Q3 25 | $129.0M | $10.8M | ||
| Q2 25 | $102.0M | $-4.8M | ||
| Q1 25 | $272.0M | $1.9M | ||
| Q4 24 | $81.0M | $-7.2M | ||
| Q3 24 | $-24.0M | $7.7M | ||
| Q2 24 | $205.0M | $11.1M | ||
| Q1 24 | $196.0M | $5.4M |
自由现金流率BF.BMED
| Q4 25 | 10.3% | -8.8% | ||
| Q3 25 | 14.0% | 12.0% | ||
| Q2 25 | 11.4% | -4.5% | ||
| Q1 25 | 26.3% | 1.6% | ||
| Q4 24 | 7.4% | -6.1% | ||
| Q3 24 | -2.5% | 5.5% | ||
| Q2 24 | 21.3% | 6.6% | ||
| Q1 24 | 18.3% | 3.1% |
资本支出强度BF.BMED
| Q4 25 | 2.4% | 1.8% | ||
| Q3 25 | 3.4% | 1.5% | ||
| Q2 25 | 5.6% | 1.3% | ||
| Q1 25 | 4.3% | 1.3% | ||
| Q4 24 | 2.8% | 1.9% | ||
| Q3 24 | 4.3% | 1.0% | ||
| Q2 24 | 8.3% | 1.1% | ||
| Q1 24 | 6.5% | 1.1% |
现金转化率BF.BMED
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.94× | — | ||
| Q2 25 | 1.04× | -1.36× | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.09× | 8.04× | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 0.93× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BF.B
| Whiskey | $771.0M | 74% |
| Ready To Drink | $138.0M | 13% |
| Tequila | $67.0M | 6% |
| Restofportfolio | $52.0M | 5% |
| Nonbrandedandbulk | $8.0M | 1% |
MED
暂无分部数据
